Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787968 · ClinicalTrials.gov registry record
Congenital Transmission of Lineages I and II of Trypanosoma Cruzi
A clinical trial, sponsored by Tulane University School of Public Health and Tropical Medicine.
- Completed
- Registry status
- 28,348
- Enrollment target
NCT01787968 is a clinical trial that has completed, run by Tulane University School of Public Health and Tropical Medicine. The registered enrollment target is 28,348 participants.
The verdict
NCT01787968 has completed, sponsored by Tulane University School of Public Health and Tropical Medicine.
- COMPLETED
- Registry status
- 28,348 participants
- Enrollment target
Study Summary
T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII, including all non-TcI). TcI is predominant in Mexico and Central America, while TcII (non-TcI) is predominant in most of South America, including Argentina. In recent studies from Argentina, the risk of congenital transmission has been estimated to vary between 2.6 percent and 7.9 percent. By contrast, we know very little about the congenital transmission of TcI. It has been suggested that congenital transmission of T. cruzi is strain related, and there is an urgent need to know if TcI transmits differently than TcII (non-TcI). Our primary hypothesis is that congenital transmission rates are different for TcI versus TcII. Our secondary hypothesis is that the characteristics of T. cruzi infected mothers (e.g., age, parity, transmission in previous pregnancies) and their exposure to vectors are different in regions where TcI is predominant versus regions where TcII (non-TcI) is predominant. To test these hypotheses, we propose to conduct a prospective study to enroll at delivery 13,000 women in Mexico, 7,500 women in Honduras, and 10,000 women in Argentina. We will measure transmitted maternal T. cruzi antibodies in cord blood, and, if the results are positive, we will identify infants who are congenitally infected by performing parasitological examinations on cord blood and at 4-8 weeks, and serological follow-up at 10 months. We will also perform standard PCR, real-time quantitative PCR, and T. cruzi genotyping on maternal blood, standard PCR and T. cruzi genotyping on the cord blood of congenitally infected newborns, and serological examinations on siblings. We will estimate the exposure to vectors in the household. In addition, we will measure prenatal outcomes among infected and uninfected infants with seropositive mothers, and the birth weight of their siblings. The specific aims of this study are: 1) To determine the rate of congenital transmission of TcI compared to TcII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28,348 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01787968
The ClinicalTrials.gov registry entry for NCT01787968 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28,348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University School of Public Health and Tropical Medicine, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01787968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01787968 about?
NCT01787968 is a clinical study titled "Congenital Transmission of Lineages I and II of Trypanosoma Cruzi". T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII, including all non-TcI). TcI is predominant in Mexico and Central America, while TcII (non-TcI) is predominant in most of South America, including Argentina. In recent studies from Argentina, the risk of congeni...
What is the current status of trial NCT01787968?
This trial is currently completed. The enrollment target is 28,348 participants. The study started on 2011-04. Estimated completion is 2013-12.
Who is sponsoring clinical trial NCT01787968?
This trial is sponsored by Tulane University School of Public Health and Tropical Medicine, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.